ARA-290 (Cibinetide): The Complete Research Guide

What is ARA-290 (Cibinetide)?

ARA-290, also known as cibinetide, is an 11-amino-acid linear peptide drawn from the helix B region of erythropoietin (EPO). EPO is best known as the hormone that signals the bone marrow to produce red blood cells, but researchers have long noted that it also carries a separate, tissue-protective activity that is chemically distinct from that blood-building role. ARA-290 was designed to isolate that second activity. It reproduces the tissue-protective surface of the EPO molecule while leaving out the part responsible for red blood cell production.

That single distinction is what makes the peptide interesting on a research bench. Full erythropoietin cannot be used freely as a tissue-protective research tool because raising red blood cell mass and blood viscosity confounds the picture. ARA-290 was developed by Araim Pharmaceuticals precisely to separate the two effects, so that the repair and anti-inflammatory signalling could be studied on its own. In the literature it is sometimes grouped with the pyroglutamate helix B surface peptide (pHBSP), and cibinetide is the international non-proprietary name assigned to it.

Mechanism and receptor targets

The classical erythropoietin receptor that drives red blood cell production is a homodimer, meaning two identical EPO receptor units paired together. Research describes ARA-290 as barely engaging that homodimeric receptor at all, which is the accepted explanation for why it is not associated with the rise in red blood cell mass seen with EPO itself.

Instead, ARA-290 is studied as a selective agonist of what researchers call the innate repair receptor (IRR). The IRR is described as a heteromeric complex, a pairing of the EPO receptor (EPOR) with the beta-common receptor, also written as the CD131 or beta-common subunit that is shared with several immune signalling receptors. This EPOR and beta-common heteromer is the switch that research associates with how tissue responds to injury, ischaemia and inflammation, as opposed to how the marrow responds to low oxygen.

Once the innate repair receptor is engaged, the downstream signalling reported in the research literature is broadly protective and anti-inflammatory. Commonly cited pathways include the following.

• Activation of pro-survival cascades such as JAK2 and STAT signalling, and the PI3K and Akt axis, which are studied in the context of reducing cell death (apoptosis) after injury.
• Modulation of inflammatory tone, including reduced release of pro-inflammatory cytokines and a shift in macrophage behaviour toward a repair-oriented state.
• Effects on the local tissue microenvironment that research links to improved recovery of nerve fibres and small blood vessels after damage.
• A tissue-protective response that, unlike EPO, is reported without a corresponding increase in red blood cell count or blood viscosity.

What ARA-290 is studied for

Because the innate repair receptor sits at the intersection of tissue protection, nerve health and inflammation, ARA-290 appears across several distinct research fields. The areas below are research contexts described in the scientific literature. They are not claims about what the compound does in a person, and nothing here is medical advice.

• Neuropathic pain and small-fibre neuropathy research, where the peptide is investigated in models of damaged small nerve fibres and the pain signalling associated with them.
• Tissue protection and ischaemia research, including models of ischaemia and reperfusion injury where the interest is in limiting cell death after blood flow is disrupted and restored.
• Inflammation research, given the peptide's reported influence on cytokine release and immune cell behaviour.
• Metabolic research, where studies have examined ARA-290 in the context of glucose handling and inflammation in metabolic models.
• Ophthalmic and microvascular research, including investigation of small nerve fibres and the tiny vessels that supply them, such as work involving corneal nerve fibre density as a measurable endpoint.
• Wound healing and neuroprotection research, where the anti-apoptotic and repair-oriented signalling is the point of interest.

A recurring theme across these fields is measurable structural endpoints. Rather than relying on subjective readouts alone, researchers studying ARA-290 have used quantifiable measures such as corneal nerve fibre density and intraepidermal nerve fibre counts, which is one reason the small-fibre neuropathy field features so prominently in the published record.

The research landscape

ARA-290 has a more developed clinical research history than many peptides that circulate in the research community. It was advanced by Araim Pharmaceuticals and progressed into human clinical trials, most notably in sarcoidosis-associated small-fibre neuropathy, a condition where inflammation damages the small nerve fibres. Published phase 2 work in that setting reported changes in patient-reported neuropathic symptoms alongside objective measures such as corneal nerve fibre density.

Beyond the sarcoidosis programme, the compound has been examined in diabetic and metabolic research, in diabetic macular oedema and retinal microvascular work, and in a range of preclinical tissue-injury models covering nerve, kidney, heart and other tissues. The consistent thread is the innate repair receptor and the tissue-protective, anti-inflammatory signalling it governs.

How ARA-290 is handled in a research setting

ARA-290 is supplied as a lyophilised (freeze-dried) powder in a sealed vial. In a research setting, lyophilised peptides are reconstituted with a suitable diluent, most commonly bacteriostatic water, before being handled in the laboratory. The information below is general research reference material about how peptides of this class are stored and prepared. It is not a protocol and it is not personal dosing guidance.

• Storage of the sealed, freeze-dried vial is typically kept cold and away from light, with long-term storage generally colder than short-term working storage.
• Reconstitution is performed with bacteriostatic water added slowly against the inside wall of the vial, allowing the powder to dissolve without agitation rather than shaking.
• Once reconstituted, peptide solutions are generally kept refrigerated and treated as time-limited, since peptides in solution are less stable than the dry powder.
• Careful record keeping of batch numbers, reconstitution volume and dates is standard laboratory practice for traceability.

Sourcing and verification: why the COA matters

For a peptide studied at this level of detail, identity and purity are not optional extras, they are the foundation of any credible research. A vial is only useful if you can confirm that its contents are actually ARA-290 and that the material is clean enough to trust. That confirmation comes from an independent Certificate of Analysis (COA).

Every batch supplied by NovaPeptides carries a verified Novagen Certificate of Analysis. Novagen Analytical Labs tests the material and issues a certificate you can open and check yourself on the lab's own register, rather than a static image that could belong to anything. A genuine COA lets a researcher confirm the essentials before any work begins.

• Identity, confirming the material is the peptide it is labelled as.
• Purity, expressed as a percentage from chromatographic analysis, so trace impurities are visible rather than hidden.
• Mass or molecular weight confirmation, tying the sample to the correct sequence.
• A unique batch reference and verification key, so the certificate can be matched to the exact vial in hand.

Why researchers choose NovaPeptides

NovaPeptides is Australian owned and based on the Gold Coast, and we have supplied research peptides to Australians for over three years. In a category where anonymous overseas sellers are common, a transparent and established local supplier is exactly what removes the guesswork, and it is why hesitant buyers tend to settle once they see the paperwork behind the product.

• A verified Novagen Certificate of Analysis on every batch, checkable on the lab's own register with a unique key.
• Australian owned and Gold Coast based, with same-day dispatch and discreet, tracked delivery Australia wide.
• Over three years supplying research peptides to Australian researchers.
• A choice of the single vial or a complete research kit. The Full Kit adds everything needed to reconstitute and handle the compound, including a reusable dosing pen, bacteriostatic water, a mixing syringe, needle tips and a travel case.
• Standard tracked shipping is $10 and Express tracked is $20 Australia wide, with free Express shipping once an order is over $250.

The single-peptide research kit format means that instead of a loose vial arriving with nothing to support it, everything needed for careful research handling arrives together in one box, ready to assemble. Research use only.

Research use status in Australia

Everything described in this guide relates to what ARA-290 is investigated for in a research context, drawn from the scientific literature. Peptides referenced here are investigational. Descriptions of receptors, signalling pathways and research areas explain how the compound is studied. They are not statements about outcomes in people.

Researchers are responsible for understanding and complying with the laws and institutional requirements that apply to acquiring, storing and handling research materials in their state or territory. NovaPeptides supplies ARA-290 as a catalogue and education product for that research and laboratory use, with a verified Novagen Certificate of Analysis on every batch.

Frequently asked questions

Related guides